13F filer · CIK 1697748 ↗
ARK Invest
You are looking at Q1 2017. See the latest, Q2 2026 →
Reported value
$346.9M
+26% on the quarter before
Positions
104
7 new · 5 sold out
Top 10
43.7%
of the value
Est. gain
+$43.8M
on stocks held all quarter
Est. return
+17.8%
on those stocks since Q4 2016
Positions as of Mar 31, 2017, from ARK Invest's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q4 2016. Striped tiles are options.
Largest buys
Since Q4 2016, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Editas Medicine Inc~$5.1MNew · 0.0% → 1.5%+229,922 shares
- Ionis Pharmaceuticals Inc~$4.9MAdded · 0.1% → 1.5%+120,942 shares
- Qualcomm~$4.7MAdded · 0.2% → 1.5%+82,346 shares
- Xilinx Inc~$4.3MAdded · 0.2% → 1.4%+73,600 shares
- Stratasys Ltd~$4.2MAdded · 7.0% → 8.1%+206,742 shares
- Twitter Inc~$4.1MAdded · 2.6% → 3.1%+275,337 shares
- IBM~$3.9MNew · 0.0% → 1.1%+22,575 shares
- Amazon~$3.4MAdded · 4.8% → 5.5%+3,851 shares
- PayPal~$2.5MAdded · 1.2% → 1.8%+57,239 shares
- Juno Therapeutics Inc~$2.4MAdded · 1.0% → 1.6%+106,291 shares
Largest sells
Since Q4 2016, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Illumina Inc~$6.2MCut · 7.3% → 5.9%−36,228 shares
- Alnylam Pharmaceuticals Inc~$6.0MCut · 1.7% → 0.1%−117,506 shares
- Netflix~$4.7MCut · 3.5% → 1.9%−31,912 shares
- Nvidia~$3.6MCut · 4.0% → 2.2%−33,004 shares
- 3-D Sys Corp Del~$3.4MCut · 1.5% → 0.4%−228,180 shares
- Alphabet~$2.5MCut · 3.4% → 2.2%−3,021 shares
- Foundation Medicine Inc~$1.3MCut · 1.9% → 2.4%−39,163 shares
- Teradyne~$1.1MCut · 1.6% → 1.2%−36,851 shares
- Meta~$1.1MCut · 2.8% → 2.4%−7,993 shares
- Kite Pharma Inc~$780,874Cut · 1.6% → 2.0%−9,949 shares
Holdings
As of Mar 31, 2017. Changes are in shares against Dec 31, 2016, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stratasys LtdSHS · shares +18% · price +23.9% | 8.1% | $27.9M | +$4.6M | ||||||||
| Athenahealth IncCOM · shares −2.7% · price +7.1% | 7.4% | $25.6M | +$1.7M | ||||||||
| Illumina IncCOM · shares −23% · price +33.3% | 5.9% | $20.5M | +$5.1M | ||||||||
| AmazonCOM · shares +22% · price +18.2% | 5.5% | $19.1M | +$2.4M | ||||||||
| BaiduSPON ADR REP A · shares +19% · price +4.9% | 3.9% | $13.6M | +$537,049 | ||||||||
| Twitter IncCOM · shares +62% · price −8.3% | 3.1% | $10.7M | −$599,156 | ||||||||
| Proto Labs IncCOM · shares +2.0% · price −0.5% | 2.6% | $9.2M | −$44,631 | ||||||||
| Foundation Medicine IncCOM · shares −13% · price +82.2% | 2.4% | $8.3M | +$3.8M | ||||||||
| Invitae CorpCOM · shares +13% · price +39.3% | 2.4% | $8.3M | +$2.1M | ||||||||
| MetaCL A · shares −12% · price +23.5% | 2.4% | $8.2M | +$1.6M | ||||||||
| Hortonworks IncCOM · shares −7.8% · price +18.1% | 2.2% | $7.8M | +$1.2M | ||||||||
| NvidiaCOM · shares −32% · price +2.1% | 2.2% | $7.7M | +$154,847 | ||||||||
| AlphabetCAP STK CL C · shares −25% · price +7.5% | 2.2% | $7.5M | +$525,554 | ||||||||
| Bluebird Bio IncCOM · shares +9.3% · price +47.3% | 2.2% | $7.5M | +$2.2M | ||||||||
| Splunk IncCOM · shares +15% · price +21.8% | 2.1% | $7.4M | +$1.2M | ||||||||
| 2u IncCOM · shares +7.5% · price +31.5% | 2.1% | $7.3M | +$1.6M | ||||||||
| Seres Therapeutics IncCOM · shares +28% · price +13.8% | 2.0% | $7.1M | +$674,450 | ||||||||
| Kite Pharma IncCOM · shares −10% · price +75.0% | 2.0% | $6.9M | +$2.9M | ||||||||
| NetflixCOM · shares −41% · price +19.4% | 1.9% | $6.7M | +$1.1M | ||||||||
| SalesforceCOM · shares +1.0% · price +20.5% | 1.9% | $6.6M | +$1.1M | ||||||||
| TeslaCOM · shares +24% · price +30.2% | 1.8% | $6.3M | +$1.2M | ||||||||
| PayPalCOM · shares +68% · price +9.0% | 1.8% | $6.1M | +$298,450 | ||||||||
| Lendingclub CorpCOM · shares +18% · price +4.6% | 1.7% | $5.9M | +$218,130 | ||||||||
| Juno Therapeutics IncCOM · shares +75% · price +17.7% | 1.6% | $5.5M | +$474,422 | ||||||||
| Exone CoCOM · shares +20% · price +9.1% | 1.5% | $5.2M | +$365,574 | ||||||||
| Total · 104 positions | 100% | $346.9M | +$43.8M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q4 2016 to Q1 2017: 97 stocks held throughout, up $43.8M (+17.8%).
- Illumina Inc+$5.1M+33%
- Stratasys Ltd+$4.6M+24%
- Foundation Medicine Inc+$3.8M+82%
- Kite Pharma Inc+$2.9M+75%
- Amazon+$2.4M+18%
- Exa Corp−$74,066−17%
- Organovo Hldgs Inc−$95,794−6%
- Conformis Inc−$129,195−35%
- Compugen Ltd−$176,454−16%
- Twitter Inc−$599,156−8%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | $15.40B+20% | SEC ↗ |
| Q1 2026 | May 12, 2026 | $12.86B−15% | SEC ↗ |
| Q4 2025 | Feb 11, 2026 | $15.07B−10% | SEC ↗ |
| Q3 2025 | Nov 12, 2025 | $16.80B+23% | SEC ↗ |
| Q2 2025 | Jul 30, 2025 | $13.64B+37% | SEC ↗ |
| Q1 2025 | May 7, 2025 | $9.99B−17% | SEC ↗ |
| Q4 2024 | Feb 4, 2025 | $12.01B+10% | SEC ↗ |
| Q3 2024 | Oct 31, 2024 | $10.93B−3% | SEC ↗ |
| Q2 2024 | Jul 26, 2024 | $11.27B−22% | SEC ↗ |
| Q1 2024 | Apr 18, 2024 | $14.44B−14% | SEC ↗ |
| Q4 2023 | Jan 17, 2024 | $16.89B+29% | SEC ↗ |
| Q3 2023 | Oct 18, 2023 | $13.07B−13% | SEC ↗ |
| Q2 2023 | Jul 10, 2023 | $15.10B+4% | SEC ↗ |
| Q1 2023 | Apr 17, 2023 | $14.55B+26% | SEC ↗ |
| Q4 2022 | Jan 24, 2023 | $11.54B−20% | SEC ↗ |
| Q3 2022 | Oct 17, 2022 | $14.35B−15% | SEC ↗ |
| Q2 2022 | Jul 11, 2022 | $16.91B−29% | SEC ↗ |
| Q1 2022 | Apr 18, 2022 | $23.96B−28% | SEC ↗ |
| Q4 2021 | Jan 28, 2022 | $33.08B−21% | SEC ↗ |
| Q3 2021 | Nov 12, 2021 | $41.64B−23% | SEC ↗ |
| Q2 2021 | Aug 5, 2021 | $53.74B+7% | SEC ↗ |
| Q1 2021 | May 13, 2021 | $50.34B+34% | SEC ↗ |
| Q4 2020 | Feb 12, 2021 | $37.59B+123% | SEC ↗ |
| Q3 2020 | Oct 30, 2020 | $16.86B+81% | SEC ↗ |
| Q2 2020 | Aug 11, 2020 | $9.30B+132% | SEC ↗ |
| Q1 2020 | May 14, 2020 | $4.01B+1% | SEC ↗ |
| Q4 2019 | Jan 31, 2020 | $3.96B−13% | SEC ↗ |
| Q3 2019 | Nov 12, 2019 | $4.58B+15% | SEC ↗ |
| Q2 2019 | Jul 30, 2019 | $3.97B+13% | SEC ↗ |
| Q1 2019 | May 13, 2019 | $3.50B+42% | SEC ↗ |
| Q4 2018 | Feb 11, 2019 (amended) | $2.46B−26% | SEC ↗ |
| Q3 2018 | Nov 7, 2018 | $3.31B+21% | SEC ↗ |
| Q2 2018 | Aug 7, 2018 | $2.73B+36% | SEC ↗ |
| Q1 2018 | May 14, 2018 | $2.01B+60% | SEC ↗ |
| Q4 2017 | Feb 12, 2018 | $1.26B+53% | SEC ↗ |
| Q3 2017 | Nov 9, 2017 | $819.3M+60% | SEC ↗ |
| Q2 2017 | Aug 11, 2017 | $513.6M+48% | SEC ↗ |
| Q1 2017 | May 15, 2017 | $346.9M+26% | SEC ↗ |
| Q4 2016 | Feb 13, 2017 | $274.9M | SEC ↗ |